Capricor Therapeutics, Inc. (CAPR): Price and Financial Metrics
CAPR Price/Volume Stats
Current price | $6.79 | 52-week high | $8.22 |
Prev. close | $6.77 | 52-week low | $2.68 |
Day low | $6.60 | Volume | 185,000 |
Day high | $6.94 | Avg. volume | 277,179 |
50-day MA | $4.81 | Dividend yield | N/A |
200-day MA | $4.59 | Market Cap | 213.91M |
CAPR Stock Price Chart Interactive Chart >
CAPR POWR Grades
- CAPR scores best on the Growth dimension, with a Growth rank ahead of 68.62% of US stocks.
- CAPR's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
- CAPR ranks lowest in Stability; there it ranks in the 14th percentile.
CAPR Stock Summary
- CAPRICOR THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 1.99% of US listed stocks.
- With a price/sales ratio of 11.37, CAPRICOR THERAPEUTICS INC has a higher such ratio than 90.56% of stocks in our set.
- As for revenue growth, note that CAPR's revenue has grown 782.77% over the past 12 months; that beats the revenue growth of 99.01% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to CAPRICOR THERAPEUTICS INC are FDMT, MRSN, ANAB, VERV, and TSVT.
- CAPR's SEC filings can be seen here. And to visit CAPRICOR THERAPEUTICS INC's official web site, go to www.capricor.com.
CAPR Valuation Summary
- In comparison to the median Healthcare stock, CAPR's price/sales ratio is 386.36% higher, now standing at 10.7.
- Over the past 202 months, CAPR's price/sales ratio has gone up 5.5.
Below are key valuation metrics over time for CAPR.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
CAPR | 2023-12-29 | 10.7 | -84.2 | -5.1 | -4.9 |
CAPR | 2023-12-28 | 10.8 | -85.2 | -5.2 | -5.0 |
CAPR | 2023-12-27 | 11.1 | -87.5 | -5.3 | -5.1 |
CAPR | 2023-12-26 | 10.5 | -82.7 | -5.1 | -4.8 |
CAPR | 2023-12-22 | 9.8 | -76.6 | -4.7 | -4.5 |
CAPR | 2023-12-21 | 9.8 | -77.0 | -4.7 | -4.5 |
CAPR Growth Metrics
- Its year over year net cashflow from operations growth rate is now at 186.85%.
- Its year over year price growth rate is now at -18.51%.
- Its 3 year net income to common stockholders growth rate is now at -61.61%.
The table below shows CAPR's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 1.591566 | 6.191106 | -27.48914 |
2022-06-30 | 0 | 8.538784 | -25.04984 |
2022-03-31 | 0.204082 | 10.56661 | -22.68869 |
2021-12-31 | 0.244898 | -16.80932 | -20.02252 |
2021-09-30 | 0.302728 | -15.02414 | -18.00993 |
2021-06-30 | 0.319591 | -14.66378 | -17.98824 |
CAPR's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CAPR has a Quality Grade of D, ranking ahead of 11.34% of graded US stocks.
- CAPR's asset turnover comes in at 0.008 -- ranking 401st of 682 Pharmaceutical Products stocks.
- DRNA, MYMD, and PCRX are the stocks whose asset turnover ratios are most correlated with CAPR.
The table below shows CAPR's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.008 | 1 | 14.774 |
2021-03-31 | 0.004 | 1 | 15.634 |
2020-12-31 | 0.010 | 1 | 19.771 |
2020-09-30 | 0.019 | 1 | -10.307 |
2020-06-30 | 0.034 | 1 | -6.657 |
2020-03-31 | 0.095 | 1 | -5.229 |
CAPR Price Target
For more insight on analysts targets of CAPR, see our CAPR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $10.50 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Capricor Therapeutics, Inc. (CAPR) Company Bio
Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company was founded in 2005 and is based in Beverly Hills, California.
Latest CAPR News From Around the Web
Below are the latest news stories about CAPRICOR THERAPEUTICS INC that investors may wish to consider to help them evaluate CAPR as an investment opportunity.
Capricor Therapeutics (NASDAQ:CAPR) shareholders are up 16% this past week, but still in the red over the last five yearsOver the last month the Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) has been much stronger than before, rebounding by... |
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis--Favorable Interim Futility Analysis Results-- --Successful Completion Triggers First Milestone Payment Under U.S. Agreement with Nippon Shinyaku-- --HOPE-3 (Cohort A) Enrollment Complete; Topline Data Expected in the Fourth Quarter of 2024; Cohort B Enrollment Initiated-- --Company Plans to Request a Meeting with FDA in the First Quarter of 2024 to Further Discuss Opportunities for Expedited Approval Pathways-- SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), |
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call TranscriptCapricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good afternoon, ladies and gentlemen and welcome to the Capricor’s Third Quarter 2023 Financial Results and Corporate Update Call. This conference call is being recorded. I would now like to turn the conference call over to our host, Mr. AJ Bergmann, Capricor’s […] |
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update-Completed Targeted Enrollment for HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy- -On Track to Report Interim Futility Analysis in Fourth Quarter of 2023; Successful Outcome Would Trigger Milestone Payment to Capricor Under Commercialization and Distribution Deal with Nippon Shinyaku- -Positive FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002’s Path Towards a Biologics License Application Submission- -Conference Call and Webcast Today |
CAPR Price Returns
1-mo | 56.81% |
3-mo | 38.85% |
6-mo | 98.54% |
1-year | 57.54% |
3-year | 46.97% |
5-year | 45.61% |
YTD | 38.85% |
2023 | 26.68% |
2022 | 31.74% |
2021 | -14.58% |
2020 | 167.97% |
2019 | -68.78% |
Continue Researching CAPR
Want to do more research on Capricor Therapeutics Inc's stock and its price? Try the links below:Capricor Therapeutics Inc (CAPR) Stock Price | Nasdaq
Capricor Therapeutics Inc (CAPR) Stock Quote, History and News - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...